Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Ridker, Paul M, Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter +6 more·2008·New England Journal of Medicine
DOI 10.1056/nejmoa0807646

Cited by (1,053)

Items 901–1,000 of 1,053

  1. An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia
    Diana Gesto, C.M.S.B. Pereira, Nuno M. F. S. A. Cerqueira, Sérgio Filipe Sousa · 2020 · Molecules
  2. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    2009 · Clinical Governance An International Journal
  3. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease
    Doroteia Silva, António Pais de Lacerda · 2012 · Revista Portuguesa de Cardiologia (English Edition)
  4. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
    RICHARD J. KONES · 2013 · Vascular Health and Risk Management
  5. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases
    Allegra Battistoni, Speranza Rubattu, Massimo Volpe · 2011 · International Journal of Cardiology
  6. A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients
    Matthew J. Feinstein, Chad J. Achenbach, Neil J. Stone, Donald M. Lloyd‐Jones · 2015 · The American Journal of Cardiology
  7. Cellular and molecular mechanisms of statins: an update on pleiotropic effects
    Mamoru Satoh, Yuji Takahashi, Tsuyoshi Tabuchi, Yoshitaka Minami, Makiko Tamada, Kan Takahashi, Tomonori Itoh, Yoshihiro Morino, Motoyuki Nakamura · 2015 · Clinical Science
  8. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Pitchai Balakumar, Sonam Kathuria, Gaurav Taneja, Sanjeev Kalra, Nanjaian Mahadevan · 2011 · Journal of Molecular and Cellular Cardiology
  9. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial
    Victor Novack, Jean G. MacFadyen, Atul Malhotra, Yaniv Almog, Robert J. Glynn, Paul M. Ridker · 2012 · Canadian Medical Association Journal
  10. HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial.
    Jennifer M. Gilbert, Kathleen V. Fitch, Steven Kyle Grinspoon · 2015 · Europe PMC (PubMed Central)
  11. Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease
    Tejas P. Singh, D.R. Morris, Samuel L. Smith, Joseph Vaughan Moxon, Jonathan Golledge · 2017 · European Journal of Vascular and Endovascular Surgery
  12. Anti-inflammatory approaches to ischaemic stroke prevention
    Peter J. Kelly, Séan Murphy, Sarah A. Coveney, Francisco F. Purroy, Robin Lemmens, Georgios K. Tsivgoulis, Christopher Price · 2017 · Journal of Neurology Neurosurgery & Psychiatry
  13. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
    Julius L. Katzmann, Ioanna Gouni‐Berthold, Ulrich Laufs · 2020 · Frontiers in Physiology
  14. Update on statin-mediated anti-inflammatory activities in atherosclerosis
    Fabrizio Montecucco, François Mach · 2009 · Seminars in Immunopathology
  15. A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
    Robert P. Hebbel, G M Vercellotti, Karl A. Nath · 2009 · Cardiovascular & Haematological Disorders - Drug Targets
  16. Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -
    Tomáš Kovárník, Gary S. Mintz, Hana Skalická, Aleš Král, Jan Horák, Roman Škulec, Jana Uhrová, Pavel Martasek E, Richard Downe, Andreas Wahle et al. · 2011 · Circulation Journal
  17. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: The Jackson Heart Study
    Jiankang Liu, Solomon K. Musani, Aurelian Bidulescu, J. Jeffrey Carr, James G. Wilson, Herman A. Taylor, Caroline S. Fox · 2012 · Atherosclerosis
  18. Metabolic syndrome: nature, therapeutic solutions and options
    Altan Onat · 2011 · Expert Opinion on Pharmacotherapy
  19. Inflammation and Cardiovascular Disease: The Future
    Natalie Arnold, Katharina Lechner, Christoph Waldeyer, Michael David Shapiro, Wolfgang Köenig · 2021 · European Cardiology Review
  20. The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus
    Helena Enocsson, Jesper Karlsson, Haiyun Li, Yi Wu, Irving Kushner, Jonas Wetterö, Christopher Sjöwall · 2021 · Journal of Clinical Medicine
  21. Implications of Increased C-Reactive Protein for Cardiovascular Risk Stratification in Black and White Men and Women in the US
    Mary Cushman, Leslie Ain McClure, Virginia J. Howard, Nancy S. Jenny, Susan C. Gilchrist, George Howard · 2009 · Clinical Chemistry
  22. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification
    Mortensen, Martin Bødtker, Falk, Erling, Li, Dong, Nasir, Khurram, Blaha, Michael J., Sandfort, Veit, Rodriguez, Carlos Jose, Ouyang, Pamela, Budoff, Matthew · 2018 · JACC: Cardiovascular Imaging
  23. Curing atherosclerosis should be the next major cardiovascular prevention goal
    Robinson, Jennifer G., Gidding, Samuel S. · 2014 · Journal of the American College of Cardiology
  24. Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity
    Matteo Pirro, Vanessa Bianconi, Francesco Paciullo, Massimo Raffaele Mannarino, Francesco Bagaglia, Amirhossein Sahebkar · 2017 · Pharmacological Research
  25. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers
    Luke Joseph Laffin, Dennis Bruemmer, M. Gómez García, Danielle M. Brennan, Ellen Strauss McErlean, Douglas S. Jacoby, Erin D. Michos, Paul M. Ridker, Tracy Y. Wang, Karol E. Watson et al. · 2022 · Journal of the American College of Cardiology
  26. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie Mitchell Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew Jay Budoff, Javed Butler, David Z.I. Cherney et al. · 2024 · Metabolism
  27. Update on the NCEP ATP-III emerging cardiometabolic risk factors
    Robert H. Eckel, Marc‐André Cornier · 2014 · BMC Medicine
  28. Association of inflammatory markers with angiographic severity and extent of coronary artery disease
    Maria I. Drakopoulou, Konstantinos P. Toutouzas, Elli Stefanadi, Eleftherios G. Tsiamis, Dimitris Tousoulis, Christodoulos Stefanadis · 2009 · Atherosclerosis
  29. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
    Mosenzon, Ofri, Capehorn, Matthew S., De Remigis, Alessandra, Rasmussen, Søren, Weimers, Petra, Rosenstock, Julio · 2022 · Cardiovascular Diabetology
  30. Practical use of the Framingham risk score in primary prevention: Canadian perspective.
    N. John Bosomworth · 2011 · Europe PMC (PubMed Central)
  31. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment
    Stephen Franklin Weng, Joe Kai, Indra Neil Guha, Nadeem Qureshi · 2015 · Open Heart
  32. Immunometabolic function of cholesterol in cardiovascular disease and beyond
    Laurent Yvan‐Charvet, Fabrizia Bonacina, Rodolphe Guinamard, Giuseppe Danilo Norata · 2019 · Cardiovascular Research
  33. C ‐reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells
    Fang Bian, Xiaoyan Yang, Fan Zhou, Pinhui Wu, Shasha Xing, Gao Xu, Wenjing Li, Jiangyang Chi, Changhan Ouyang, Yonghui Zhang et al. · 2014 · British Journal of Pharmacology
  34. Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice
    Lucie Poupel, Alexandre Boissonnas, Patricia Hermand, Karim Dorgham, Elodie Guyon, Constance Auvynet, Flora Saint-Charles, Philippe Lesnik, Philippe Déterre, Christophe Combadière · 2013 · Arteriosclerosis Thrombosis and Vascular Biology
  35. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence
    Maki, Kevin C., Bays, Harold E., Dicklin, Mary R. · 2012 · Journal of Clinical Lipidology
  36. Interaction between periodontal disease and atherosclerotic vascular disease – Fact or fiction?
    Ghazal Aarabi, Jörg Eberhard, Daniel Ralph Reissmann, Guido Heydecke, Udo Seedorf · 2015 · Atherosclerosis
  37. Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?
    Paul M. Ridker · 2012 · Current Atherosclerosis Reports
  38. The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
    Karen E. Porter, Kirsten Riches‐Suman · 2013 · Clinical Science
  39. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris
    Toshio Imanishi, Hideyuki Ikejima, Hiroto Tsujioka, Akio Kuroi, Kohei Ishibashi, Kenichi Komukai, Takashi Tanimoto, Yasushi Ino, Tatsuya Takeshita, Takashi Akasaka · 2010 · Atherosclerosis
  40. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
    George Thanassoulis, Ken Williams, Kathleen K. Altobelli, Michael J. Pencina, Christopher Paul Cannon, Allan D. Sniderman · 2016 · Circulation
  41. The Pleiotropic Effects of Statins – From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia
    Adam Oesterle, James K. Liao · 2018 · Current Vascular Pharmacology
  42. Clinical approach to the inflammatory etiology of cardiovascular diseases
    Massimiliano Ruscica, Alberto Corsini, Nicola Ferri, Maciej Banach, Cesare Riccardo Sirtori · 2020 · Pharmacological Research
  43. 2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension
    Chern‐En Chiang, Tzung‐Dau Wang, Yi-Heng Li, Tsung‐Hsien Lin, Kuo‐Liong Chien, Hung‐I Yeh, Kou‐Gi Shyu, Wei-Chuen Tsai, Ting-Hsing Chao, Juey‐Jen Hwang et al. · 2010 · Journal of the Formosan Medical Association
  44. How I treat the antiphospholipid syndrome
    Bill Giannakopoulos, Steven A. Krilis · 2009 · Blood
  45. Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors
    Vasilios Gabriel Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Κωνσταντίνος Τζιόμαλος, A. Peletidou, C. Vosikis, Asterios I. Karagiannis, Dimitri P. Mikhailidis · 2009 · Nutrition Metabolism and Cardiovascular Diseases
  46. Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
    Marie Fisk, Parag Ravindra Gajendragadkar, Kaisa M. Maki-Petaja, Ian B. Wilkinson, Joseph Cheriyan · 2014 · American Journal of Cardiovascular Drugs
  47. Toward Clinically Applicable Biomarkers in Bipolar Disorder: Focus on BDNF, Inflammatory Markers, and Endothelial Function
    Benjamin I. Goldstein, Lionel Trevor Young · 2013 · Current Psychiatry Reports
  48. Socioeconomic status in childhood and C reactive protein in adulthood: a systematic review and meta-analysis
    Richard Liu, Allison E. Aiello, Fiona K. Mensah, Constantine E Gasser, Kuna Rueb, Billie Cordell, Markus Juonala, Melissa A Wake, David Paul Burgner · 2017 · Journal of Epidemiology & Community Health
  49. Atherosclerosis
    Mohammed Shamim Rahman, Kevin J. Woollard · 2017 · Advances in experimental medicine and biology
  50. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
    Panagiotis Tsioufis, Panagiotis Theofilis, Konstantinos P Tsioufis, Dimitris Tousoulis · 2022 · International Journal of Molecular Sciences
  51. Atherosclerosis in Systemic Lupus Erythematosus
    George Stojan, Michelle Petri · 2013 · Journal of Cardiovascular Pharmacology
  52. Valsartan
    Henry R. Black, Jacqueline Bailey, Dion Zappe, Rita Samuel · 2009 · Drugs
  53. Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
    Johann Auer, Helmut F. Sinzinger, Barry Franklin, Robert Berent · 2014 · European Journal of Preventive Cardiology
  54. High-sensitivity C-reactive protein predicts mortality but not stroke
    Mitchell S.V. Elkind, Jorge M. Luna, Yeseon Park Moon, K. M. Liu, Steven L. Spitalnik, Myunghee Cho Paik, Ralph L. Sacco · 2009 · Neurology
  55. Treatment Options for Statin-Associated Muscle Symptoms
    Ulrich Laufs, Hubert Scharnagl, Martin Halle, Eberhard Windler, Matthias Endres, Winfried März · 2015 · Deutsches Ärzteblatt international
  56. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy
    Yoo-Ri Chung, Sung Wook Park, Shin-Young Choi, Seung Woo Kim, Ka Young Moon, Jeong Hun Kim, Kihwang Lee · 2017 · Cardiovascular Diabetology
  57. FDA drug safety communications: a narrative review and clinical considerations for older adults
    Marcum, Zachary A., Vande Griend, Joseph P., Linnebur, Sunny A. · 2012 · The American Journal of Geriatric Pharmacotherapy
  58. Assessing the Clinical Utility of Diagnostics Used in Drug Therapy
    Janet Woodcock · 2010 · Clinical Pharmacology & Therapeutics
  59. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates
    Mira T. Keddis, Vesna D. Garovic, Kent R. Bailey, Christopher Wood, Yassaman Raissian, Joseph Peter Grande · 2010 · Nephrology Dialysis Transplantation
  60. Role of C-reactive protein in cerebrovascular disease: a critical review
    Mario Di Napoli, Mitchell S.V. Elkind, Daniel Agustín Godoy, Puneetpal Singh, Francesca Papa, Aurel Popa‐Wagner · 2011 · Expert Review of Cardiovascular Therapy
  61. Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review
    Cristiano Fava, Martina Montagnana · 2018 · Frontiers in Pharmacology
  62. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner
    Jianqing She, Gulinigaer Tuerhongjiang, Manyun Guo, Junhui Liu, Xiang Hao, Liangan Guo, Nairong Liu, Wen Xi, Tao Zheng, Bin Du et al. · 2024 · Cell Metabolism
  63. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
    Stefano Romeo, Antonio Vidal‐Puig, Mansoor Husain, Rexford S. Ahima, Marcello Arca, Deepak L. Bhatt, Anna Mae Diehl, Luigi Fontana, Roger Foo, Gema Frühbeck et al. · 2025 · European Heart Journal
  64. Nontraditional Risk Factors for Ischemic Stroke
    Oh Young Bang, Bruce I Ovbiagele, Jong Sung Kim · 2015 · Stroke
  65. Endothelium, venous thromboembolism and ischaemic cardiovascular events
    Stefania Momi, Rino Migliacci, Paolo Gresele · 2009 · Thrombosis and Haemostasis
  66. Levels of C-Reactive Protein Associated with High and Very High Cardiovascular Risk Are Prevalent in Patients with Rheumatoid Arthritis
    Jonathan D. Graf, Rebecca Scherzer, Carl Grünfeld, John B. Imboden · 2009 · PLoS ONE
  67. Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound
    Niki, Toshiyuki, Wakatsuki, Tetsuzo, Yamaguchi, Koji, Taketani, Yoshio, Oeduka, Hiroyasu, Kusunose, Kenya, Ise, Takayuki, Iwase, Takashi, Yamada, Hirotsugu, Soeki, Takeshi et al. · 2016 · Circulation Journal
  68. The effect of subantimicrobial-dose–doxycycline periodontal therapy on serum biomarkers of systemic inflammation
    Jeffrey B. Payne, Lorne M. Golub, Julie Ann Stoner, Hsi‐Ming Lee, Richard A. Reinhardt, Timo A. Sorsa, Marvin J. Slepian · 2011 · The Journal of the American Dental Association
  69. Statins: Is It Really Time to Reassess Benefits and Risks?
    Allison B. Goldfine · 2012 · New England Journal of Medicine
  70. Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward
    Kevin Jon Williams, Xiangdong Wu · 2016 · Atherosclerosis
  71. Cardiovascular risk assessment in women – an update
    Peter D. Collins, Carolyn M. Webb, T. J. de Villiers, John C. Stevenson, Nick Panay, Rod Baber · 2016 · Climacteric
  72. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes
    João Sérgio Neves, Connie B. Newman, John Bostrom, Martin Buysschaert, Jonathan D. Newman, José Luís Medina, Ira J. Goldberg, Michael Bergman · 2022 · Diabetes Research and Clinical Practice
  73. Statins and risk of type 2 diabetes: mechanism and clinical implications
    Laakso, Markku, Fernandes Silva, Lilian · 2023 · Frontiers in Endocrinology
  74. From genetic associations to genes: methods, applications, and challenges
    Ting Qi, Liyang Song, Yazhou Guo, Chang Chen, Jian Yang · 2024 · Trends in Genetics
  75. Consensus statement on management of dyslipidemia in Indian subjects
    K. Sarat Chandra, Manish Bansal, Tiny Nair, Shamanna Seshadri Iyengar, Rajeev Gupta, Subhash Chand Manchanda, Padinhare Purayil Mohanan, V. Dayasagar Rao, C.N. Manjunath, J.P.S. Sawhney et al. · 2014 · Indian Heart Journal
  76. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
    D. Preiss, N. Sattar · 2009 · Clinical Endocrinology
  77. Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy
    Daniel Gologorsky, Aristomenis Thanos, Demetrios G. Vavvas · 2012 · Mediators of Inflammation
  78. Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis
    Angela D. Armendariz, Ronald M. Krauss · 2009 · Current Opinion in Lipidology
  79. Biomarker-guided personalised emergency medicine for all – hope for another hype?
    Philipp Schüetz, Drahomir Aujesky, Christian Eugen Mueller, Beat Peter Müller-Stich · 2015 · Swiss Medical Weekly
  80. Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
    Gyeong Joon Moon, Suk Jae Kim, Yeon Hee Cho, Sookyung Ryoo, Oh Young Bang · 2014 · Journal of Clinical Neurology
  81. C-Reactive Protein and Risk of Venous Thromboembolism in the General Population
    Jeppe Zacho, Anne Tybjærg‐Hansen, Børge Grønne Nordestgaard · 2010 · Arteriosclerosis Thrombosis and Vascular Biology
  82. The Health Costs of Cost-Sharing
    Amitabh Chandra, Evan Flack, Ziad Obermeyer · 2021 · National Bureau of Economic Research
  83. Recent Advances in Preventive Cardiology and Lifestyle Medicine
    Barry A. Franklin, Mary Cushman · 2011 · Circulation
  84. National Lipid Association Annual Summary of Clinical Lipidology 2015
    Harold Edward Bays, Peter H. Jones, William Virgil Brown, Terry A. Jacobson · 2014 · Journal of clinical lipidology
  85. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
    Kimberly N. Hong, Valentı́n Fuster, Robert S. Rosenson, Clive Rosendorff, Deepak L. Bhatt · 2017 · Journal of the American College of Cardiology
  86. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
    Francesco Paciullo, Stefania Momi, Paolo Gresele · 2019 · Thrombosis and Haemostasis
  87. Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies
    Ruurt Jukema, Tarek Abdel-Hameed Nagib Ahmed, Jean‐Claude Tardif · 2019 · BMC Medicine
  88. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia
    Yvette N. Lamb · 2020 · American Journal of Cardiovascular Drugs
  89. Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort
    Nels C. Olson, Mary Cushman, Pamela L. Lutsey, Leslie Ain McClure, Suzanne E. Judd, Russell P. Tracy, Aaron R. Folsom, Neil A. Zakai · 2014 · Journal of Thrombosis and Haemostasis
  90. Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
    Nicholas Funderburg, Magdalena Kalinowska, James Eason, James Goodrich, Jayvant Heera, Howard Mayer, Natasa Rajicic, Hernán Valdez, Michael M. Lederman · 2010 · PLoS ONE
  91. Orally Administered Eicosapentaenoic Acid Induces Rapid Regression of Atherosclerosis Via Modulating the Phenotype of Dendritic Cells in LDL Receptor-Deficient Mice
    Kenji Nakajima, Tomoya Yamashita, Tomoyuki Kita, Masafumi Takeda, Naoto Sasaki, Kazuyuki Kasahara, Masakazu Shinohara, Yoshiyuki Rikitake, Tatsuro Ishida, Mitsuhiro Yokoyama et al. · 2011 · Arteriosclerosis Thrombosis and Vascular Biology
  92. Metabolic syndrome as a risk factor for diabetes
    Pablo J. Aschner · 2010 · Expert Review of Cardiovascular Therapy
  93. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease
    Anton Nilsson, Kleoniki Tsoumani, Tereza Planck · 2021 · The Journal of Clinical Endocrinology & Metabolism
  94. Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
    Wang, Nelson, Woodward, Mark, Huffman, Mark D., Rodgers, Anthony · 2022 · Circulation: Cardiovascular Quality and Outcomes
  95. Association of Combinations of Lipid Parameters With Carotid Intima-Media Thickness and Coronary Artery Calcium in the MESA (Multi-Ethnic Study of Atherosclerosis)
    Pathmaja Paramsothy, Robert H. Knopp, Alain Gerald Bertoni, Roger Scott Blumenthal, Bruce Alan Wasserman, Michael Y. Tsai, Tessa C. Rue, Nathan D. Wong, Susan R. Heckbert · 2010 · Journal of the American College of Cardiology
  96. Effect of interleukin 1β inhibition in cardiovascular disease
    Arman Qamar, Daniel James Rader · 2012 · Current Opinion in Lipidology
  97. Ancestry as a Determinant of Mean Population C-Reactive Protein Values
    Tina Shah, Paul J. Newcombe, Liam L Smeeth, Juliet Addo, Juan Pablo Casas, John C. Whittaker, Michelle A. Miller, Lorna Tinworth, Steve Jeffery, Pasquale Strazzullo et al. · 2010 · Circulation Cardiovascular Genetics
  98. CETP Inhibition: Past Failures and Future Hopes
    Constantine E. Kosmas, Eddy DeJesus, Digna Rosario, Timothy J. Vittorio · 2016 · Clinical Medicine Insights Cardiology
  99. The role of inflammation in cardiovascular diseases: the predictive value of neutrophil–lymphocyte ratio as a marker in peripheral arterial disease
    Feliciano Chanana Paquissi · 2016 · Therapeutics and Clinical Risk Management
  100. Identification and Management of Cardiometabolic Risk after Spinal Cord Injury
    Nash, Mark S., Groah, Suzanne L., Gater, David R., Dyson-Hudson, Trevor A., Lieberman, Jesse A., Myers, Jonathan, Sabharwal, Sunil, Taylor, Allen J. · 2019 · The Journal of Spinal Cord Medicine